Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 3Recurrence 2Esophageal Neoplasms 2Recurrent Squamous Cell Lung Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Gliosarcoma 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Oxaliplatin 14Fluorouracil 11Capecitabine 9Surveys and Questionnaires 8Leucovorin 8Irinotecan 8Cisplatin 8Bevacizumab 8Standard of Care 5Gemcitabine 5Drug Therapy 4S 1 (combination) 3Radiotherapy 3Nivolumab 3Interviews as Topic 3IFL protocol 3Educational Status 3Cyclophosphamide 3Colonoscopy 3Blood Specimen Collection 35,10-methylenetetrahydrofolic acid 3trebananib 2tivozanib 2pembrolizumab 2Taxes 2Remote Patient Monitoring 2Pemetrexed 2Panitumumab 2Ocoxin 2N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gastrointestinal Neoplasms × rilotumumab × Clear all
NCT00788957 2024-08-07

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

NantBioScience, Inc.

Phase 1/2 Completed
177 enrolled 31 charts
Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡